Clinical Trials Logo

Pigmented Skin Lesion clinical trials

View clinical trials related to Pigmented Skin Lesion.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04202419 Completed - Clinical trials for Pigmented Skin Lesion

Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions

Start date: January 9, 2020
Phase: N/A
Study type: Interventional

This study is being conducted to evaluate the safety and efficacy of a fractional diode laser for treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sunspots), and ephelides (freckles).

NCT ID: NCT02848742 Completed - Clinical trials for Pigmented Skin Lesion

Dermal Cryotherapy for Treatment of Pigmented Lesions

Start date: June 2016
Phase: N/A
Study type: Interventional

Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign pigmented lesions.

NCT ID: NCT02613325 Completed - Melanoma Clinical Trials

fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth

Start date: June 8, 2015
Phase: Phase 1
Study type: Interventional

The investigators propose the use of functional photoacoustic microscopy (fPAM) to evaluate both benign and malignant pigmented lesions for tumor depth. Through fPAM analysis followed by histological examination, the investigators anticipate that they will be able to non-invasively determine tumor depth of pigmented lesions (moles and melanoma). In melanoma, tumor depth (Breslow's depth) is not only an important prognostic indicator, but also directs surgical treatment. The ultimate goal is to develop a sensitive clinical tool that will allow non-surgical evaluation of pigmented lesions, which eventually, will aid in melanoma diagnosis and management - potentially an earlier and more definitive surgical management. In addition, the investigators propose to use the combination of fPAM and single-cell PAM to respectively image CTCs in trunk vessels and cuticle capillaries. Based on the investigators' murine models, the investigators anticipate that they will be able to differentiate CTCs from other blood cells and reliably calculate CTC concentration in a non-invasive manner. CTC concentration has been demonstrated to be a valuable indicator of a melanoma's metastatic potential and a potential tool in evaluating treatment efficacy. The ultimate goal is to develop a sensitive imaging device that will allow accurate evaluation of the risk of melanoma recurrence and metastases, that may facilitate treatment monitoring.